(19)
(11) EP 1 569 685 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.12.2012 Bulletin 2012/49

(45) Mention of the grant of the patent:
08.08.2012 Bulletin 2012/32

(21) Application number: 03796403.8

(22) Date of filing: 13.11.2003
(51) International Patent Classification (IPC): 
C07K 14/705(2006.01)
A61K 39/00(2006.01)
 A61K 39/395(2006.01)
C07K 16/28(2006.01)
(86) International application number:
PCT/US2003/036459
(87) International publication number:
WO 2004/045520 (03.06.2004 Gazette 2004/23)

(54)

COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS

KOMPLEMENT-MODULATOREN FÜR KOMPLEMENT-REZEPTOR 2

MODULATEURS DE COMPLEMENT CIBLES SUR LE RECEPTEUR 2 DE COMPLEMENT

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 15.11.2002 US 426676 P

(43) Date of publication of application:
07.09.2005 Bulletin 2005/36

(60) Divisional application:
10010735.8 / 2292259

(73) Proprietors:
  • MUSC Foundation For Research Development
    Charleston, SC 29403 (US)
  • The Regents of the University of Colorado, A Body Corporate
    Denver, CO 80203 (US)

(72) Inventors:
  • TOMLINSON, Stephen
    Mt. Pleasant, SC 29466 (US)
  • HOLERS, V. Michael
    Denver, CO 80220 (US)

(74) Representative: Roques, Sarah Elizabeth 
J A Kemp 14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
US-B1- 6 458 360
   
  • HARRIS C L ET AL: "Tailoring anti-complement therapeutics." BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 30, no. Pt 6, 20 November 2002 (2002-11-20), pages 1019-1026, XP002371833 ISSN: 0300-5127
  • SONG ET AL: 'Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation' J. CLIN. INVEST. vol. 111, no. 12, June 2003, pages 1875 - 1885, XP002981946
  • MULLIGAN ET AL: 'Endothelial Targeting and Enhanced Antiinflammatory Effects of Complement Inhibitors Possessing Sialyl Lewisx Moieties' J. IMMUNOL. vol. 162, 1999, pages 4952 - 4959, XP002981947
  • SMITH ET AL: 'Membrane-targeted complement inhibitors' MOL. IMMUNOL. vol. 38, 2001, pages 249 - 255, XP002981948
  • ZHANG ET AL: 'Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface' J. BIOL. CHEM. vol. 276, no. 29, July 2001, pages 27290 - 27295, XP002981949
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).